The positive results and favourable safety profile from the BRF113928 trial led to the approval of the combination of dabrafenib and trametinib for the treatment of BRAF V600E metastatic NSCLC patients, regardless of previous therapy [54,55]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.